MBX
MBX Biosciences, Inc.
37.02
1 x 26.64
1 x 45.51
bid
ask
-
0.48
1.27%
10:08 AM
timesize
| Ytd | 17.39% | |
| 1y | 264.06% |
35.31
day range
37.88
9.43
52 week range
45.85
| Open | 37.10 | Prev Close | 37.50 | Low | 35.31 | High | 37.88 | Mkt Cap | 1.76B |
| Vol | 37.47K | Avg Vol | 568.19K | EPS | -2.17 | P/E | N/A | Forward P/E | -9.38 |
| Beta | N/A | Short Ratio | 8.74 | Inst. Own | 109.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 31.28 | 200-d Avg | 26.12 | 1yr Est | 64.36 |
| Income Statement | |||
| Operating Expenses | 25.80M | ||
| Research and Development Expense | 19.76M | ||
| Selling, General and Administrative Expense | 6.04M | ||
| Operating Income | -25.79M | ||
| Net Income | -22.06M | ||
| Net Income Common Stock | -22.06M | ||
| Net Income Common Stock (USD) | -22.06M | ||
| Consolidated Income | -22.06M | ||
| Earnings per Basic Share | -0.45 | ||
| Earnings per Basic Share (USD) | -0.45 | ||
| Earnings per Diluted Share | -0.45 | ||
| Earning Before Interest & Taxes (EBIT) | -22.06M | ||
| Earning Before Interest & Taxes (USD) | -22.06M | ||
| Weighted Average Shares | 36.51M | ||
| Weighted Average Shares Diluted | 36.51M | ||
| Balance Sheet | |||
| Cash and Equivalents | 75.29M | ||
| Cash and Equivalents (USD) | 75.29M | ||
| Investments | 298.42M | ||
| Investments Current | 298.42M | ||
| Current Assets | 381.54M | ||
| Property, Plant & Equipment Net | 3.22M | ||
| Total Assets | 385.14M | ||
| Debt Current | 172.00K | ||
| Total Debt | 596.00K | ||
| Current Liabilities | 15.50M | ||
| Debt Non-Current | 424.00K | ||
| Total Liabilities | 15.92M | ||
| Accumulated Retained Earnings (Deficit) | -224.48M | ||
| Accumulated Other Comprehensive Income | 286.00K | ||
| Shareholders Equity | 369.22M | ||
| Shareholders Equity (USD) | 369.22M | ||
| Assets Non-Current | 3.61M | ||
| Total Debt (USD) | 596.00K | ||
| Liabilities Non-Current | 426.00K | ||
| Trade and Non-Trade Payables | 2.98M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 92.00K | ||
| Net Cash Flow from Financing | 438.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -147.84M | ||
| Capital Expenditure | -793.00K | ||
| Issuance (Purchase) of Equity Shares | 955.00K | ||
| Net Cash Flow from Investing | -129.97M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -129.18M | ||
| Net Cash Flow from Operations | -18.30M | ||
| Share Based Compensation | 2.66M | ||
